<SEC-DOCUMENT>0001213900-25-067909.txt : 20250728
<SEC-HEADER>0001213900-25-067909.hdr.sgml : 20250728
<ACCEPTANCE-DATETIME>20250728083330
ACCESSION NUMBER:		0001213900-25-067909
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250728
FILED AS OF DATE:		20250728
DATE AS OF CHANGE:		20250728

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enlivex Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001596812
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36578
		FILM NUMBER:		251153031

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		PROVINCE COUNTRY:   	L3
		BUSINESS PHONE:		972 (0) 3 7326616

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		PROVINCE COUNTRY:   	L3

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Bioblast Pharma Ltd.
		DATE OF NAME CHANGE:	20160919

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIO BLAST PHARMA LTD.
		DATE OF NAME CHANGE:	20140113
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0250366-6k_enlivex.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 6-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Report of Foreign Private Issuer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of: July 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission file number: 001-36578</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>ENLIVEX THERAPEUTICS LTD.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>14 Einstein Street, Nes Ziona, Israel 7403618</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F&nbsp;&#9744;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 28, 2025, Enlivex Therapeutics Ltd., a
company organized under the laws of the State of Israel, issued a press release announcing that that all 134 patients in its Phase II
stage of its randomized, controlled, blinded Phase I/II trial of Allocetra&trade; in patients with moderate to severe knee osteoarthritis,
have completed a follow-up period of at least three months, the trial&rsquo;s primary timepoint for measurement of key endpoints. A copy
of such press release is furnished as Exhibit 99.1 to this Report on Form 6-K and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea025036601ex99-1_enlivex.htm">Press Release issued by Enlivex Therapeutics Ltd. on July 28, 2025.</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enlivex Therapeutics Ltd.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 35%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Oren Hershkovitz</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">Name:&nbsp;</TD>
    <TD STYLE="vertical-align: top">Oren Hershkovitz</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: July 28, 2025</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B></B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea025036601ex99-1_enlivex.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY ENLIVEX THERAPEUTICS LTD. ON JULY 28, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Enlivex Reaffirms August 18, 2025 As Target
Date For Announcement of Phase II Topline Data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Nes-Ziona, Israel, July 28, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the &ldquo;Company&rdquo;), a clinical-stage macrophage reprogramming
immunotherapy company, today announced that all 134 patients in its Phase II stage of its randomized, controlled, blinded Phase I/II
trial of Allocetra&trade; in patients with moderate to severe knee osteoarthritis, have completed a follow-up period of at least
three months, the trial&rsquo;s primary timepoint for measurement of key endpoints. The data are being analyzed and audited, with a
target date of August 18, 2025 for the public release of audited topline results for three-month key endpoints, including safety and
change from baseline in knee pain and function.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The multi-center Phase I/II clinical trial consists
of two stages. The first stage was a Phase I safety run-in, open-label dose escalation phase to characterize the safety and tolerability
of Allocetra&trade; injections to the target knee, in order to identify the dose and injection regimen or the subsequent Phase IIa stage.
This stage is a double-blind, randomized, placebo-controlled multi-centered trial. In addition to evaluating safety, the study protocol
is designed to efficiently find a strong signal in a responder population to guide future development, and includes an interim statistical
evaluation, conducted by an independent third party and blinded to the Company, to assess the potential value of enrollment of up to 50
patients in addition to the original randomized sample size of 130, and its marginal impact on the p-value of the statistical estimation
of the total group and specifically to identify a potential responder sub-group. The trial&rsquo;s key efficacy endpoints evaluate joint-pain
and joint-function in comparison to placebo at three months, six months and 12 months post treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ABOUT KNEE OSTEOARTHRITIS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Osteoarthritis is by far the most common form
of arthritis, affecting more than 32.5 million Americans and more than 300 million individuals worldwide. About half of knees with ACL
injuries develop osteoarthritis within 5 to 15 years. 78 million Americans are projected to have osteoarthritis by the year 2040. Symptomatic
knee osteoarthritis is particularly prevalent and disabling, with 40% of men and 47% of women developing knee osteoarthritis in their
lifetimes. Osteoarthritis accounts for over one million hospitalizations annually in the United States, primarily for total joint replacement.
The burden of osteoarthritis is enormous, and the need for treatments that reduce pain and attendant disability for persons with osteoarthritis
is critical. There are currently no medications approved by either the U.S. Food and Drug Administration (FDA) or the European Medicines
Agency (EMA) that have been demonstrated to arrest, slow or reverse progression of structural damage in the joint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ABOUT ENLIVEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Enlivex is a clinical stage macrophage reprogramming
immunotherapy company developing Allocetra&trade;, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their
homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution
of life-threatening and life debilitating conditions. For more information, visit&nbsp;https://enlivex.com/.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Safe Harbor Statement: This press release contains
forward-looking statements, which may be identified by words such as &ldquo;expects,&rdquo; &ldquo;plans,&rdquo; &ldquo;projects,&rdquo;
&ldquo;will,&rdquo; &ldquo;may,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;should,&rdquo; &ldquo;would,&rdquo; &ldquo;could,&rdquo;
&ldquo;intends,&rdquo; &ldquo;estimates,&rdquo; &ldquo;suggests,&rdquo; &ldquo;target,&rdquo; &ldquo;has the potential to&rdquo; and other
words of similar meaning, including statements regarding expected cash balances, expected clinical trial results, market opportunities
for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRA<SUP>TM</SUP>&nbsp;programs.
All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of
1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex&rsquo;s business
and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that
the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support
the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue
to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth
in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results
of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed,
later-stage trials. The development of any products using the ALLOCETRA<SUP>TM</SUP>&nbsp;product line could also be affected by a number
of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision
making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and
other proprietary rights held by competitors and other third parties. In addition to the risk factors described above, investors should
consider the economic, competitive, governmental, technological and other factors discussed in Enlivex&rsquo;s filings with the Securities
and Exchange Commission, including in the Company&rsquo;s most recent Annual Report on Form 20-F filed with the Securities and Exchange
Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we
do not undertake any obligation to update forward-looking statements, except as required under applicable law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ENLIVEX CONTACT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shachar Shlosberger, CFO<BR>
Enlivex Therapeutics, Ltd.<BR>
shachar@enlivexpharm.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>INVESTOR RELATIONS CONTACT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dave Gentry, CEO<BR>
RedChip Companies Inc.<BR>
1-407-644-4256<BR>
ENLV@redchip.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  J )8# 2(  A$! Q$!_\0
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MOXI?!U[9/$_BC2-#DN1_PKI4RB:G>PET5W1&,2-M+#*CD#[P_:#^*OPU\?\
M[,?[1]OX#^(7@KQC<Z;\$_B1+J-OX1\3Z1XB;3XSX3U=5EG72KR5XD=AM$D@
M16;Y0Q(Y^5Q]"I_;&!JJ_(HX!MV?*[T:#U>VC>NN_4^[RC$X=<.8["RE%22Q
MJY5)<]W5JZ6?O:WTLM='L?F'9_!J\^-7_!"OX;Z)H*[_ !CX1^ WA;XJ^ KB
MT7=>V7B_X9WA\7Z4VGD8=+ISIT^F;U.2MY(HSO&>H_;%_:(NOVC/^">/[.7A
M7P/<)'XN_;WUGX.?"M%MI=SZ?:>(KK3[_P")^0O[PG2=-TC6=-N%(.QI"),'
M)K[1_P""8MI;:A_P3J_97LYUCNK._P#@IH4%Q@JR/#<6]Q%,A +*59)&5\Y&
M>"*_)3]ACX3^,KG_ (*!2_LR>*M*E3X:_P#!-G6OC+XQ^'>J3,9!JDG[1&J1
M7_@. ELQYT'PQJ&L&$[0T9<"/;QCVL-'#XJIFTZ\X1>58C$8R,6TG5C-2@H0
MUU?M_8NT4U9NRZGSN-AB\%A\GA@XS:S:AA\+-J,G[-J<9.4K+3]SSJ[L^[/J
M#_@JO-X=^"'@O_@GU=V6CZQ>^%_A)^U5\+(K;0/"5B-3\27^B>%O#.J6D>E:
M%I*#=J&I.EE$$L(_GF$3 $.*]WT/_@K%\(]8US0M!B^ 7[7]G<:[JVFZ-;76
MH_L]>+[.QLKC4[E;97U21E=;.-&)>65MRJ@+D@ FN)_X*RW]AHFN_P#!/?5=
M6U/3=%TS3?VY?AE=7^IZK>1V-C:6JZ7X@\R22]E9(HQAEW-(50C)=A@BOT9A
M_:5_9WB5U?XY_"%&B#"0-\1/"2[2G4,?[7Q\H!W')P<GGG'G8ETI97E\Y82>
M(F_K<I2C-I+_ &B\6TD]4W?5I6T1WY>JU+B#-*?UV&&C%81<DE%7MATG9R:7
M1J\5UUU.A^-GPI\(?'+X0?$#X3>.;-;SPC\0_"&K>&=>LY%VM]BU:S:)Y""0
M4N+61HYXCN#QSPJP(*Y'\]7_  2STKQ1^T'^T_JLGQH\?>&_B /^":7AW4?V
M>/@[8Z/J/]HP>([O4=0N]*3XS7<4CN)M1/A#2M/\+IJR!A'+%<'>LF[/Z9_\
M%#OVIK[X>?LXV&@_ O5=/\7?&?\ :CUG3/@Q^SV-"U**_@O->\;/_9E[XPM[
M[3GD671_".CR7^NS:K"6CAEM[57=0W/P]\1?V>-+_P""5NK?LA?M1_#=6D\"
M^ M$\._LY_MD3V4.U/%?@WQQJ$.SXOZ\ X>?5=!^(UXVI2W$RY2VU4QR.(U*
MCHRBK&EE6/PM1Q6)Q\9?4+I-T90BW4:D]8>WA>@FFM>AS9]!XWB'*L5AE*6
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M)9?"EI+W(PYDE=*R3Z.^FG_#V"CK@ CIGG@#.<$^W&<^@]J"0 23@*"23T
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M?4\+[J="%J;3IJT;0:5DXZ:::*UK*_<\#^-G[/\ \&OVA]"TWPS\:_AWX?\
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76S^G\/D^#HT*-*,7RPI0BNFBBNA__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
